Improved drug delivery and anti-tumor efficacy of combinatorial liposomal formulation of genistein and plumbagin by targeting Glut1 and Akt3 proteins in mice bearing prostate tumor

• Published in: Colloids and surfaces, B, Biointerfaces Vol. 190; p. 110966
• Main Authors: Song, Yuan-yuan, Yuan, Ye, Shi, Xu, Che, Yuan-yuan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2020
• Subjects: Animals; antineoplastic activity; antineoplastic agents; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; blood vessels; Cell Proliferation - drug effects; Cells, Cultured; Drug delivery; Drug Delivery Systems; Drug Screening Assays, Antitumor; encapsulation; Genistein; Genistein - chemistry; Genistein - pharmacology; Glucose; Glucose Transporter Type 1 - antagonists & inhibitors; Glucose Transporter Type 1 - metabolism; Humans; Liposomes - chemistry; Male; men; Mice; Nanoliposomes; Naphthoquinones - chemistry; Naphthoquinones - pharmacology; neoplasm cells; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Particle Size; PC-3 Cells; Plumbagin; prostatic neoplasms; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Proto-Oncogene Proteins c-akt - antagonists & inhibitors; Proto-Oncogene Proteins c-akt - metabolism; signal transduction; Surface Properties; toxicity; transporters; Wound Healing - drug effects; Nanoliposomes; Drug delivery; Glucose; Plumbagin; Genistein

[Display omitted] •Development of genistein and plumbagin encapsulated nanoliposomes for prostate cancer treatment.•Formulation lead to the inhibition of PI3K/AKT3 signaling pathway and decrease in Glut-1 transporters.•The formulation showed selective anticancer effect in prostate cancer cells and t...